Xeris Biopharma Holdings Inc
2B30
Company Profile
Business description
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Contact
1375 West Fulton Street
Suite 1300
ChicagoIL60607
USAT: +1 844 445-5704
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
435
Stocks News & Analysis
stocks
Hostile takeover on the cards for this ASX income opportunity
IFM lobs reasonable takeover offer.
stocks
Get ready for major US tech earnings starting tomorrow morning
Microsoft, Amazon, Alphabet, and Meta will all release quarterly earnings. Here’s what analysts are looking for.
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,906.20 | 6.50 | 0.07% |
| CAC 40 | 8,104.09 | 37.83 | -0.46% |
| DAX 40 | 24,018.26 | 65.27 | -0.27% |
| Dow JONES (US) | 49,141.93 | 25.86 | -0.05% |
| FTSE 100 | 10,332.79 | 11.70 | 0.11% |
| HKSE | 26,054.68 | 374.90 | 1.46% |
| NASDAQ | 24,663.80 | 223.30 | -0.90% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,770.30 | 5.90 | 0.05% |
| S&P 500 | 7,138.80 | 35.11 | -0.49% |
| S&P/ASX 200 | 8,678.50 | 0.90 | 0.01% |
| SSE Composite Index | 4,106.24 | 27.60 | 0.68% |